The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

This phase II trial, designed by Peking University People’s Hospital, is a randomized, open-label, multicenter study to assess the combination treatment of tacrolimus and danazol compared to danazol alone in steroid-resistant or relapsed ITP. Individuals with primary ITP between 18-70 years old and have relapsed or did not achieve a response with corticosteroids are eligible to enrol. Participants must have a platelet count less than 30x109/L at the time of enrollment. Individuals with secondary ITP, cancer, are pregnant, or were previously treated with danazol will not be ineligible to participate in this study.



back to top

Charity NavigatorGuideStar Seal NORD Member BadgeTHSNA logo